This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The concept of congenital myopathies (CMs) as a group of genetically determined muscle disorders originally relied on clinical and histopathologic/histochemical criteria, pioneered and developed by Magee and Shy1 and by Dubowitz and Pearse.2 Clinical criteria of hypotonia and weakness, usually manifesting from birth, together with a static or slowly progressive course, are enduring concepts despite the major advances of molecular genetics in this area. These clinical criteria, together with electrophysiologic and histopathologic assessments, remain valuable tools in the differentiation of CMs from other congenital neuromuscular disorders, such as muscular dystrophies, myasthenic syndromes, and metabolic myopathies as well as polyneuropathies and neuronopathies. Nevertheless, genetic and pathogenetic criteria have recently added a few late infantile and adult-onset variants to this group of disorders and occasionally have blurred the borders between CMs and congenital neuromuscular transmission defects.3,4 The relative use of histopathologic/histochemical criteria has diminished as we have learned that CMs with similar histopathology may be caused by mutations in more than one gene, and that mutations in the same gene can result in different muscle pathologies.5,6 More recently, muscle MRI has offered additional support in the preliminary diagnostic assessment of these conditions.5–7
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 28
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
